{"product_id":"saralasin-acetate-p1150","title":"Saralasin Acetate","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003eSaralasin Acetate, an octapeptide analog of angiotensin II, is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of hypertension. The mapped target for this entry is Angiotensin II receptors type 1 and 2 (AGTR1 and AGTR2). This target context is most often investigated as part of ligand-responsive signaling, where receptor occupancy can reshape downstream second-messenger output, trafficking, secretion, excitability, or transcriptional programs. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. For experimental design, that means the peptide is often chosen to compare acute signaling with longer adaptive responses in the same system.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eAs an antagonist-format peptide, it is well suited to experiments that test pathway dependence, receptor blockade, and the extent to which a phenotype requires ongoing target signaling. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because more than one mapped molecular node is represented in the enrichment, pathway readouts should be interpreted with awareness that the phenotype may integrate multiple signaling inputs.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003epair peptide treatment with pathway-proximal signaling or trafficking readouts whenever possible\u003c\/li\u003e\n\u003cli\u003ecompare responses across cell states or model systems with different receptor abundance\u003c\/li\u003e\n\u003cli\u003edistinguish primary target engagement from downstream adaptation during longer incubations\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eExperimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.\u003c\/p\u003e\u003ch2\u003eFormat Considerations\u003c\/h2\u003e\u003cp\u003eFor routine mechanistic work, the unmodified catalog format provides a consistent starting point for concentration-response studies, benchmark experiments, and orthogonal validation. In comparative workflows, keeping the listed acetate format constant across comparator groups can reduce avoidable formulation-related differences. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"5 mg","offer_id":57636823007577,"sku":"P1150-5MG","price":285.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/p1150-saralasin-acetate-chemical-structure.png?v=1774212398","url":"https:\/\/absource.de\/products\/saralasin-acetate-p1150","provider":"Absource Diagnostics","version":"1.0","type":"link"}